罗氏与 Ascidian Therapeutics 达成 18 亿美元的合作协议，共同研发用于治疗神经系统疾病的 RNA 外显子编辑药物。 Roche partners with Ascidian Therapeutics in a $1.8B deal for RNA exon-editing drugs for neurological diseases.

罗氏与 Ascidian Therapeutics 合作达成 18 亿美元的协议，开发用于治疗神经系统疾病的 RNA 外显子编辑药物。 Roche partners with Ascidian Therapeutics in a $1.8B deal to develop RNA exon-editing drugs for neurological diseases. Ascidian 获得了 4200 万美元的首付款和潜在的里程碑付款。 Ascidian receives an initial $42M payment and potential milestone payments. 此次合作旨在利用 Ascidian 的 RNA 重写技术与罗氏的 CNS 递送能力来创造新型基因组药物，提供基因治疗的好处而没有直接的 DNA 编辑风险。 The collaboration aims to use Ascidian's RNA rewriting technology with Roche's CNS delivery capabilities to create novel genomic medicines, offering the benefits of gene therapy without direct DNA editing risks.